Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02521311 · ClinicalTrials.gov registry record · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
A Phase 2 study of Optic Neuritis, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT02521311 is a Phase 2 study of Optic Neuritis that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 90 participants, below the 787-participant average among 5 other Optic Neuritis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02521311, a Phase 2 study of Optic Neuritis, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include assessments for evidence of remyelination in the anterior visual pathway and in the brain using electrophysiologic techniques and magnetic resonance imaging. If they are on one, patients in this study can remain on their standard disease modifying treatment during the course of the study. However, patients cannot participate in any other investigational new drug research study concurrently.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Clemastine
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02521311
The ClinicalTrials.gov registry entry for NCT02521311 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 787-participant average among 5 other Optic Neuritis trials with a reported enrollment target (89% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Optic Neuritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02521311 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02521311 about?
NCT02521311 is a clinical study titled "Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)". The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include ass...
What is the current status of trial NCT02521311?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2017-02-28. Estimated completion is 2028-08.
What conditions does trial NCT02521311 study?
This clinical trial studies the following conditions: Optic Neuritis.
What interventions are being tested in trial NCT02521311?
The interventions under investigation include: Placebo (DRUG), Clemastine (DRUG).
Who is sponsoring clinical trial NCT02521311?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02521311 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Optic Neuritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efgartigimod for the Treatment of Acute Optic Neuritis
RECRUITING · Phase 2
-
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
RECRUITING · Phase 3
-
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
ACTIVE NOT RECRUITING
-
Biobank For MS And Other Demyelinating Diseases
ACTIVE NOT RECRUITING
-
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.